JPMorgan upgraded Kodiak Sciences (KOD) to Neutral from Underweight with a $15 price target The firm says the company is entering a “very catalyst-rich period” over the next two-years with key pivotal data for tarcocimab, KSI-501, and KSI-101. Kodiak shares are likely to perform more in-line with the group and “clear clinical wins” in the studies may be needed to shift investor sentiment, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD: